

Study Number	First Author Surname	Publication year	Publication Type	Study design	Country
S1	Linder	2019	Journal	single group study	USA
S2	Salgado	2017	Journal	Pilot study	Australia
S3	Spoelstra	2016	journal	RCT	USA
S4	Greer	2020	Journal	RCT	USA
S5	Sadigh	2023	Journal	Pilot study	USA
S6	Krok-Schoen	2019	Journal	Pilot study	USA
S7	Karaaslan-Esser	2021	Journal	RCT	Turkey
S8	Psihogios	2023	Journal	Pilot study	USA
S9	Yanez	2022	Journal	RCT	USA
z10	Heneghan	2021	Journal	cross-sectional survey	USA
z11	Passardi	2022	Journal	Prospective trial	Italy

Figure: Table 1

Study Number	First Author Sur name	Sample size (number of participants)	Male/female ratios in the study	Mean age of the participants
S1	Linder	23	1.556	20
S2	Salgado	9	2	54
S3	Spoelstra	75	0.83	60
S4	Greer	181	0.86	54
S5	Sadigh	29	0	57
S6	Krok-Schoen	39	0	59
S7	Karaaslan-Esser	84	1.2	60
S8	Psihogios	18	3.5	19
S9	Yanez	95	0	33
S10	Heneghan	64	0.6	parents 39, patients 17
S11	Passardi	40	0.6667	42-82

Figure: Table 2

Cancer categorization	Grand Total	References
Mixed malignancies	2	Greer S4, LinderS1
Hematologic malignancy	3	Heneghan S10, Psihogios S8, Salgado S2
Solid tumors	6	Karaaslan-Esser S7, Krok-Schoen S6, Passardi S11, Sadigh S5, Spoelstra S3 , Yanez S9
Grand Total	11	

Figure: Table 3

Categorized cancer medications	Grand Total	Reference
Mixed	4	S4,7,1,11
oral chemotherapy	3	S10,8,3
TKI	2	S5,2
Anti hormonal therapy	2	S6,9
Grand Total	11	

Figure: Table 4

Name of the feature	Grand Total	Reference
Reminders	11	S1,2,3,4,5,6,7,8,9,10,11
Adherence assessment	10	S1,2,4,5,6,7,8,9,10,11
Side effects reporting	5	S2,3,4,6,11
Patient Education	5	S2,3,4,7,11
Symptoms assessment	4	S3,4,6,11
Interaction with clinicians	3	S2,5,11
E-capsules	2	S1,4
Interaction with other users	2	S2,11
Patient feedback	2	S8,9
Medication information	2	S7,10
Confirms administration	1	S3
Drug-drug interaction	1	S11
Signs assessment	1	S11
Refill reminder	1	S10
referral request	1	S5
Calendar sync	1	S7

Figure: Table 5

Adherence assessment	Grand Total	Reference
Author-specific questionnaire/App generated	9	S1,2,3,5,7,8,9,10,11
Morisky Medication Adherence Scale	2	S4,6
Adherence outcome	Total	Reference
Negative	2	S4, S9
Neutral	1	S10
Positive	8	S7,6,1,11,8,5,2,3

Figure: Table 6

Compatibility	Grand Total	Reference
Laptop/desktop and Smartphones IOS/Android	3	S11,2,9
Smartphones IOS/Android	7	S4,7,6,1,8,5,3
Smartphones, Tablets, IOS/Android	1	S10
System characteristic	Total	Reference
Stand alone	6	S4,7,6,1,8,3
Web page	3	S5,2,9
App and webpage	1	S10
Not reported	1	S11

Figure: Table 7